Daily Archives: February 24, 2020
P052 VALIDITY AND INTERPRETABILITY OF PROMIS PEDIATRIC PATIENT-REPORTED OUTCOMES FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE
Patient-Reported Outcome Measurement Information System (PROMIS) instruments were developed using rigorous psychometric methods to assess health and quality of life across the life course. In two studies, we aimed to evaluate the clinical validity of P… Continue reading
P080 A PROSPECTIVE LONGITUDINAL STUDY OF PROTON PUMP INHIBITORS EFFECT ON INFLAMMATORY BOWEL DISEASE FLARES AND ACTIVITY
Proton pump inhibitors (PPIs) are one of the most commonly prescribed medications in the United States. Some recent studies have suggested that PPIs may have a negative effect on the gut microbiome. Dysbiosis of the gut microbiome has been linked with … Continue reading
P051 USING A HUMAN-CENTERED QUALITATIVE RESEARCH APPROACH FOR DEVELOPING IBD EDUCATIONAL VIDEOS DELIVERED THROUGH SOCIAL MEDIA
Patients with inflammatory bowel disease (IBD) can have knowledge gaps regarding their disease and its management, which may lead to anxiety and reduced quality of life. They often use social media as a tool to seek information and manage their chronic… Continue reading
P092 COMPARISON OF INFLIXIMAB AND ADALIMUMAB CONCENTRATIONS BETWEEN THE ENZYME-LINKED IMMUNOSORBENT ASSAY AND THE HOMOGENEOUS MOBILITY SHIFT ASSAY (HMSA) IN INFLAMMATORY BOWEL DISEASE: AN UPDATE FOLLOWING IMPLEMENTATION OF CORRECTIVE MEASURES FOR THE HMSA
We previously showed a discrepancy between a commercially available enzyme-linked immunosorbent assay (ELISA) and the homogenous mobility shift assay (HMSA) for both infliximab and adalimumab concentrations in patients with inflammatory bowel disease (… Continue reading
P050 SUBSTANCE USE OCCURS FREQUENTLY IN PATIENTS WITH CROHN’S DISEASE
Crohn’s disease (CD) is an inflammatory disease of the gut with multiple psychosocial comorbidities, including lost wages, stress on loved ones, and psychiatric illnesses, all of which are associated with substance use disorders. While approximately 7…. Continue reading
P087 REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN ULCERATIVE COLITIS
Ulcerative colitis (UC) is a chronic inflammatory condition of the colon. Ustekinumab is a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23 FDA approved for use in Crohn’s disease. A recent randomized control trial UNIFI [San… Continue reading
P049 RESPONSIVENESS OF THE PATIENT-REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM (PROMIS) TO CHANGES IN DISEASE STATUS AND QUALITY OF LIFE AMONG PEDIATRIC PATIENTS WITH CROHN’S DISEASE
Patient Reported Outcome Measurement Information System (PROMIS) provides valid, self-reported measures of physical, emotional, and social health that can inform research and clinical care in children with chronic conditions. Prior research in pediatri… Continue reading
P083 CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT INFLAMMATORY BOWEL DISEASE COHORT COMBINING HIGH-RESOLUTION PHENOTYPING WITH BIOSAMPLE COLLECTION TO FACILITATE PRECISION MEDICINE: SPARC IBD
Disease location, behavior, and average activity over time vary significantly amongst patients with inflammatory bowel disease (IBD). Despite this heterogeneity patients are often subjected to a “one size fits all” treatment plan. Clinical and multi-om… Continue reading
P048 QUALITY OF LIFE AND OTHER PATIENT REPORTED OUTCOMES IN PATIENTS WITH POUCHITIS
While restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred surgical approach in patients with medically refractory ulcerative colitis (UC) or UC-related dysplasia, a significant proportion of patients develop pouchitis … Continue reading
P093 IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN’S DISEASE
Certolizumab pegol (CZP) is effective treatment for moderately-to-severely active Crohn’s disease (CD)1, 2 at approved subcutaneous doses of 400 mg on weeks 0, 2 and 4 (induction) and every 4 weeks thereafter (maintenance). Prior research has demonstra… Continue reading